Opinion of the Transparency Council – sulfamethoxazolum + trimethoprimum
At its meeting on 17 March 2025, the Transparency Council adopted opinion No. 47/2025 on the reimbursement of medicines containing the active substances sulfamethoxazolum + trimethoprimum for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. for the prevention of infections in bone marrow transplant patients